Healthcare Business

As the number of baby boomers grows, so does the worry that health care costs will rocket higher in the United States. The oldest of the boomers are nearly 75 and the youngest are 57. The current...
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
These four Jefferies stock picks in the health care space offer outstanding upside potential for investors long term and look like very solid ideas for the rest of 2021, especially with an overbought...
Here are five biotech stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny...
A couple of Cathie Wood's Ark Invest funds bought over 1 million shares of Iovance Bio on May 20.
There are about 900,000 doctors in America, and the U.S. has among the highest ratios of doctors to the population of any country in the world. Doctors make an average of $270,000 a year and work an...
There are about 900,000 doctors in America, and the U.S. has among the highest ratios of doctors to the population of any country in the world. Doctors make an average of $270,000 a year and work an...
There are about 900,000 doctors in America, and the U.S. has among the highest ratios of doctors to the population of any country in the world. Doctors make an average of $270,000 a year and work an...
These five super-aggressive biotech stocks are all rated Buy at well-known Wall Street firms and are suitable for very aggressive investors that have a high-risk tolerance.
Frequency Therapeutics shares were absolutely crushed on Tuesday but saw a bit of a recovery early Wednesday.
Amazon on Wednesday announced an expansion of its health care service to all employers in Washington state. The announcement took a bite out of some competing health care stocks.
Rubius Therapeutics was one of Monday’s biggest winners after it announced initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Drugs, whether they are generic, OTC, or patented, are affordable to most Americans, particularly those who have healthcare that covers the cost of pharmaceuticals. However, in rare cases, drugs can...
Novavax stock jumped to close out the week after the firm announced the final efficacy numbers for its COVID-19 vaccine candidate.